Source-grounded facts extracted from Serina Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Serina Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $6.9 million, EPS $(0.58) per basic and diluted share.
“Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.”
Serina Therapeutics, Inc.: Amended and restated bylaws to include provisions relating to appointment and authority of Co-Chairs of the Board of Directors, and conforming updates (effective 2026-04-15).
“On April 15, 2026, the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company (the " Bylaws "), effective immediately. The Bylaws include provisions relating to the appointment of Co-Chairs of the Board of Directors, including provisions clarifying that special meetings of stockholders may be called by the Chair or any Co-Chair, that the Chair or any Co-Chair may preside at meetings of stockholders and meetings of the Board of Directors, and that each Co-Chair has the same authority and powers as the Chair of the Board and may act independently of any other Co-Chair, subject to coordination expectations set forth in the Bylaws.”
Serina Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $19.4 million, EPS $(1.91) per basic and diluted share.
“The net loss attributable to Serina common stockholders for the year ended December 31, 2025 was $19.4 million, or $(1.91) per basic and diluted share”
Serina Therapeutics, Inc.: Company agreed to amend bylaws to provide for co-chairmen of the Board, with each co-chairman having same rights and responsibilities, effective upon closing of initial tranche of private placement.
“the Company has agreed to take all necessary actions to effect such appointment and to amend its bylaws to provide for co-chairmen of the Board, with each co-chairman having the same rights and responsibilities.”
Serina Therapeutics, Inc. amended a notes offering with holders of its outstanding Senior Unsecured Convertible Promissory Note.
“As a condition to the initial closing, the Company and the holders of its outstanding Senior Unsecured Convertible Promissory Note, dated September 9, 2025, entered into an amendment of such note, effective upon the initial closing, removing any further obligations to borrow or loan funds under the Note.”
Serina Therapeutics, Inc. entered into Securities Purchase Agreement with Greg Bailey, as lead investor, and certain other investors valued at $15.0 million (effective 2026-03-17).
“On March 17, 2026, Serina Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Greg Bailey, as lead investor, and certain other investors (collectively, the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), pre-funded warrants to purchase shares of Common Stock (the “ Pre-Funded Warrants ”) redeemable warrants to purchase shares of Common Stock (the “ Redeemable Warrants ” and, together with the Common Stock and the Pre-Funded Warrants, the “ Securities ”).”
Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii), 1009).
“January 9, 2026, Serina Therapeutics, Inc. (the “Company”) received a notification (the “Letter”) from The NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, (ii) $4.0 million or more if the Company has reported losses”
Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.
“equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as”
Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.
“note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at”
Serina Therapeutics, Inc. incurred convertible notes of up to $20 million with Gregory H. Bailey, M.D. at annual rate of 10% maturing five years after the initial funding date.
“On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an unsecured convertible note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million.”
Serina Therapeutics, Inc.: Amended bylaws to add safe harbor procedures for interested transactions and expand the forum selection clause (effective 2025-08-18).
“On August 18, 2025, the Board of Directors of Serina Therapeutics, Inc. (the “Company”) amended the Company’s Amended and Restated Bylaws (the “Bylaws Amendment”) to (i) provide a number of safe harbor procedures for acts or transactions involving the Company in which one or more directors or officers as well as controlling stockholders and members of control groups have interests or relationships that might render them interested or not independent with respect to the act or transaction and (ii) supplement the forum selection clause in Section 9.2 of the Company’s Amended and Restated Certificate of Incorporation to expand the coverage of the forum selection clause to include claims of stockholders, when acting in their capacity as stockholders or in the right of the corporation, if such claims relate to the business of the corporation, the conduct of its affairs, or the rights or powers of the corporation or its stockholders, directors or officers.”
Remy Gross departed as Director at Serina Therapeutics, Inc..
“The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.”
Stephen Brannan was appointed as Director at Serina Therapeutics, Inc..
“On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.”
Serina Therapeutics, Inc.: Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-04-10).
“On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designations") with the Secretary of State of the State of Delaware, which became effective upon filing.”
Dr. Milton Harris departed as Director at Serina Therapeutics, Inc..
“The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .”
Dr. Jay Venkatesan was appointed as Director at Serina Therapeutics, Inc..
“On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.”
Steven Mintz departed as Director at Serina Therapeutics, Inc..
“departure of Steven Mintz from its Board of Directors”
Karen J. Wilson was appointed as Director at Serina Therapeutics, Inc..
“appointment of Karen J. Wilson to the Company’s Board of Directors, effective January 14, 2025”
Serina Therapeutics, Inc. completed a disposition involving JuvVentures (UK) Limited for assumed approximately $11.2 million of secured debt (closed 2024-12-23).
“with the intent to revert aged or diseased cells to a healthy and functional state. As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of”
Steven Ledger was appointed as Chief Executive Officer at Serina Therapeutics, Inc..
“On September 8, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Steven Ledger, the current Interim Chief Executive Officer of the Company, to be the Company’s Chief Executive Officer.”
Andrea Park departed as Interim Chief Financial Officer and Chief Accounting Officer at Serina Therapeutics, Inc..
“On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.”
Gregory S. Curhan was appointed as Chief Financial Officer at Serina Therapeutics, Inc..
“On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.”
Srini Tenjarla was appointed as Senior Vice President, CMC & Formulation at Serina Therapeutics, Inc..
“On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.”
Tacey Viegas departed as Chief Operating Officer at Serina Therapeutics, Inc..
“On July 9, 2024, Tacey Viegas, Chief Operating Officer of Serina Therapeutics, Inc. (the “ Company ”), notified the Company that he will retire effective July 15, 2024”
Serina Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively, net income $9.4 million, or ($3.38) per share (basic and diluted), EPS ($3.38) per share (basic and diluted).
“On May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024.”
Serina Therapeutics, Inc. dismissed WithumSmith+Brown, PC as its auditor.
“ithumSmith+Brown, PC (“ Withum ”), the Company’s independent registered public accounting firm prior to the Merger, was informed that it would be dismissed and replaced by Frazier & Deeter. The reports of Withum on the Company’s financial statements for each of the two fiscal years ended December 31, 2023 and 2022 did not”
Serina Therapeutics, Inc. engaged Frazier & Deeter, LLC as its auditor.
“pril 29, 2024, the Audit Committee of the Board of Directors of the Company approved, on behalf of the Company, the engagement of Frazier & Deeter, LLC (“ Frazier & Deeter ”) as the Company’s independent registered public accounting”
Simba Gill was appointed as Executive Chairman at Serina Therapeutics, Inc..
“On April 17, 2024, Serina Therapeutics, Inc. (the “Company”) announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective as of April 12, 2024.”
Serina Therapeutics, Inc.: Name change from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc. via Amended Certificate after Merger (effective 2024-03-26).
“Immediately after the consummation of the Merger, on March 26, 2024, AgeX filed the Amended Certificate changing its name from "AgeX Therapeutics, Inc." to "Serina Therapeutics, Inc."”
Serina Therapeutics, Inc. completed an acquisition involving AgeX Therapeutics, Inc. for issuance by AgeX of an aggregate of 5,913,277 shares of AgeX common stock (closed 2024-03-26).
“arch 26, 2024, the Delaware corporation formerly known as “AgeX Therapeutics, Inc.” completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of August 29,”
Serina Therapeutics, Inc. incurred convertible notes of an additional $2.4 million with Juvenescence Limited.
“pursuant to which AgeX drew an additional $2.4 million of its credit available under the 2022 Convertible Note”
Serina Therapeutics, Inc. entered into Merger Agreement with AgeX, Merger Sub (effective 2024-03-26).
“reviously disclosed, on August 29, 2023, AgeX, Merger Sub and Serina entered into the Merger Agreement. Upon the terms and subject to”
Richard Marshall was appointed as Class III Director at Serina Therapeutics, Inc..
“ey and Dr. Richard Marshall, appointed as Class III directors”
Gregory M. Bailey was appointed as Class III Director at Serina Therapeutics, Inc..
“The Company’s board of directors appointed the following members to the Compensation Committee: J. Milton Harris, Ph.D. (Chair), Gregory M. Bailey, M.D., and Steven Mintz.”
J. Milton Harris was appointed as Chairman of the Board at Serina Therapeutics, Inc..
“Dr. Harris was appointed Chairman of the Company’s board of directors.”
Jean-Christophe Renondin resigned as Director at Serina Therapeutics, Inc..
“Dr. Jean-Christophe Renondin resigned from AgeX’s board of directors”
Joanne M. Hackett departed as Interim Chief Executive Officer and Director at Serina Therapeutics, Inc..
“both Dr. Joanne M. Hackett and Dr. Jean-Christophe Renondin resigned from AgeX’s board of directors and all respective committee membership of AgeX’s board of directors, effective as of the effective time of the Merger and (ii) Dr. Hackett was terminated as interim CEO of the Company effective as of the effective time of the Merger.”
Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.
“On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Serina Therapeutics, Inc.: Amended the Certificate of Incorporation to effect a 1-for-35.17 reverse stock split of common stock (effective 2024-03-14).
“To effect the Reverse Stock Split, AgeX filed a Certificate of Amendment to the AgeX Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, with an effective time of 10:00 a.m. Eastern Time on March 14, 2024 (the “Effective Time”).”
Serina Therapeutics, Inc. shareholders approved Proposal No. 6 – To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the Proxy Statement/Prospectus/Information Statement. at the 2024-03-14 meeting.
“Proposal No. 6 – To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the Proxy Statement/Prospectus/Information Statement. Votes Non-Votes 71,363,789 8,360,752 71,784 437,873”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (H) To provide for the forum s at the 2024-03-14 meeting.
“(H) To provide for the forum selection provisions in the Combined Company Charter. Votes Non-Votes 68,953,348 6,695,768 64,793 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (G) To authorize provisions li at the 2024-03-14 meeting.
“(G) To authorize provisions limiting personal liability for officers of the combined company for monetary damages for breach of fiduciary duty as an officer to the extent permissible under the DGCL; and Votes Non-Votes 68,841,445 6,789,599 82,866 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (F) To provide that any action at the 2024-03-14 meeting.
“(F) To provide that any action required or permitted to be taken by stockholders of the combined company must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders; Votes Non-Votes 68,871,319 6,797,084 45,507 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (E) To create a classified boa at the 2024-03-14 meeting.
“(E) To create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years; Votes Non-Votes 69,231,707 6,459,281 22,922 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (D) To require the affirmative at the 2024-03-14 meeting.
“(D) To require the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, is required to make, alter amend or repeal the bylaws of the combined company or to adopt any provision inconsistent therewith; Votes Non-Votes 67,879,829 7,755,889 78,192 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (C) To require that any provis at the 2024-03-14 meeting.
“(C) To require that any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed, or any provision inconsistent therewith can only be adopted, upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class; Votes Non-Votes 69,208,191 6,464,926 40,793 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (B) To provide that the number at the 2024-03-14 meeting.
“(B) To provide that the number of authorized shares of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law (“DGCL”); Votes Non-Votes 69,192,423 6,447,684 73,803 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (A) To authorize the issuance at the 2024-03-14 meeting.
“(A) To authorize the issuance of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock; Votes Non-Votes 68,965,060 6,714,611 34,239 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 4 – To approve an amendment and restatement of the AgeX Charter (the “Combined Company Charter”), in the form attached as Annex B to the Proxy Statement/Prospectus/Information Statement. at the 2024-03-14 meeting.
“Proposal No. 4 – To approve an amendment and restatement of the AgeX Charter (the “Combined Company Charter”), in the form attached as Annex B to the Proxy Statement/Prospectus/Information Statement. Votes Non-Votes 68,614,107 7,040,014 59,789 4,520,288”
Serina Therapeutics, Inc. shareholders approved Proposal No. 3 – To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential iss at the 2024-03-14 meeting.
“Proposal No. 3 – To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance. Votes Non-Votes 69,026,316 6,662,323 25,271 4,520,288”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.